Wall Street Zen Downgrades Disc Medicine (NASDAQ:IRON) to Sell

Disc Medicine (NASDAQ:IRON) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts have also recently issued reports on IRON. Wedbush reissued an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. HC Wainwright raised their target price on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a research note on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Disc Medicine currently has an average rating of “Moderate Buy” and an average target price of $106.50.

Disc Medicine Stock Performance

IRON opened at $80.03 on Friday. The stock has a market capitalization of $3.07 billion, a price-to-earnings ratio of -12.16 and a beta of 1.00. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a 50-day simple moving average of $76.98 and a 200 day simple moving average of $70.02.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating the consensus estimate of ($1.71) by $0.17. Analysts predict that Disc Medicine will post -6.61 EPS for the current fiscal year.

Insider Activity

In related news, insider Rahul Khara sold 5,000 shares of Disc Medicine stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the insider directly owned 52,324 shares of the company’s stock, valued at approximately $4,185,920. The trade was a 8.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 8,796 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total transaction of $731,123.52. Following the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 153,612 shares of company stock worth $11,431,811. Corporate insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State of Wyoming acquired a new stake in shares of Disc Medicine during the 2nd quarter valued at $25,000. ANTIPODES PARTNERS Ltd acquired a new position in Disc Medicine in the 4th quarter worth about $33,000. Allworth Financial LP acquired a new position in Disc Medicine in the 2nd quarter worth about $46,000. Nykredit A S bought a new position in Disc Medicine in the second quarter valued at about $103,000. Finally, Persistent Asset Partners Ltd bought a new position in Disc Medicine in the fourth quarter valued at about $141,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.